Exelixis
NASDAQ: EXEL1 known investors
Exelixis is a biopharmaceutical company developing cancer therapies through biotherapeutics and small molecule programs, including bispecific antibodies and antibody-drug conjugates. It advances anti-cancer treatments internally and via industry collaborations across multiple modalities in biologics and small molecules.
Founder mafia
2 people who came through Exelixis went on to found or lead other companies.
Investors · 1
Competitors · 2
by search overlapBioworld175 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
ADP157 shared keywordsADP provides cloud-based human capital management solutions that integrate payroll, HR, talent management, time and attendance, tax, and benefits administration for businesses globally. The company serves as a comprehensive provider of HCM software and business outsourcing services with analytics and compliance expertise.
Companies competing with Exelixis for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law | Press Releases | daily-tribune.comdaily-tribune.com · Aug 2026
Exelixis Stock Price | EXEL Stock Quote, News, and History | Markets Insidermarkets.businessinsider.com · Aug 2026Frequently asked questions
- What does Exelixis do?
- Exelixis is a biopharmaceutical company developing cancer therapies through biotherapeutics and small molecule programs, including bispecific antibodies and antibody-drug conjugates. It advances anti-cancer treatments internally and via industry collaborations across multiple modalities in biologics and small molecules.
- Who are Exelixis's investors?
- Exelixis's investors include Atlas Venture.